10/08/2026 – AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million subscribed by a limited number of investors
10/07/2026 – AB Science today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for AML and the masitinib program for ALS
08/07/2026 – Appointment of Stéphane LEDERMANN as Chairman and Chief Executive Officer
01/07/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors
29/06/2026 – AB Science today provides an update on the Phase 1 study of the molecule AB8939 and the completion of Step 3, evaluating the combination of AB8939 + venetoclax in patients with acute myeloid leukemia
17/06/2026 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib
